Clomiphene citrate affects cervical mucus and endometrial morphology independently of the changes in plasma hormonal levels induced by multiple follicular recruitment.
OBJECTIVE
To analyze the effects of clomiphene citrate (CC) on cervical mucus (CM) and endometrial morphology independently of hormonal changes encountered when CC is administered for ovulation induction.


METHODS
Volunteers whose ovarian functions were temporarily suppressed (n = 18) by a long-acting GnRH agonist and 6 women of similar age suffering from premature ovarian failure (POF) received E2 and P. Half of the women also received CC (50 mg/d, days 2 to 6).


METHODS
Tertiary University Institution, Hôpital A. Béclère.


METHODS
Eighteen volunteers suffering from infertility not related to a uterine cause and 6 women of similar age suffering from POF.


METHODS
Plasma gonadotropins, E2, and P were measured at baseline to confirm that the ovaries were inactive and twice weekly during physiological E2 and P replacement. Cervical mucus was analyzed on day 14 and scored from 0 to 15. Endometrial biopsies were obtained on replacement days 20 and 24 for conventional histology and immunocytochemistry analysis of estrogen receptors and progesterone receptors (PR). Premature ovarian failure women whose results have been previously published served as controls for day 20 biopsies.


RESULTS
Cervical mucus scored lower in women who received CC (5.5 +/- 3.2) than in controls (13.6 +/- 4.7, mean +/- SEM). On day 20, endometrial findings were similar in women treated with CC and in controls. On day 24, specimens showed a significant delay in endometrial maturation in women treated with CC. On day 24, only staining for PR selectively persisted in endometrial stroma, and no difference was observed between women who received CC and controls.


CONCLUSIONS
Our results indicate that CC significantly alters CM quality and late luteal phase endometrial morphology despite physiological levels of plasma E2 and P. Hence, clinicians should monitor E2 levels when using CC, and caution should be exerted when supraphysiological levels of E2 are not present to counterbalance the effects of CC on the CM and the endometrium.
Service d'Endocrinologie et des Maladies de la Reproduction, Hôpital de Bicêtre, France.
M R
MR
Massai
D
D
de Ziegler
V
V
Lesobre
C
C
Bergeron
R
R
Frydman
P
P
Bouchard
D000328:Adult; D001706:Biopsy; D002582:Cervix Mucus / Q000187:drug effects*; D002996:Clomiphene / Q000494:pharmacology*; D004717:Endometrium / Q000187:drug effects* / Q000473:pathology; D004958:Estradiol / Q000097:blood* / Q000494:pharmacology; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D010062:Ovulation Induction; D011374:Progesterone / Q000097:blood* / Q000494:pharmacology; D017329:Triptorelin Pamoate / Q000031:analogs & derivatives*
D017329:Triptorelin Pamoate; D002996:Clomiphene; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; C019176:Tryptal